应激性高血糖比率:一种新的慢性肾脏疾病预后指标。

IF 3.4 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM
Tianquan Chen, Yijiao Zhu, Yushuang Liu, Hongxia Li, Zhe Han, Min Liu, Xia Xu, Rong Wang
{"title":"应激性高血糖比率:一种新的慢性肾脏疾病预后指标。","authors":"Tianquan Chen, Yijiao Zhu, Yushuang Liu, Hongxia Li, Zhe Han, Min Liu, Xia Xu, Rong Wang","doi":"10.1186/s13098-025-01639-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The stress hyperglycemia ratio (SHR) has recently been suggested to characterize acute glycemic rise better than the admission blood glucose and to be associated with unfavorable outcomes in patients with various cardiovascular diseases. This study aimed to explore the associations between SHR and all-cause or cardiovascular disease (CVD) mortality in patients with chronic kidney disease (CKD).</p><p><strong>Methods: </strong>Adults with CKD participating in the 1999-2018 US National Health and Nutrition Examination Survey with complete SHR and follow-up data were included. SHR was calculated from fasting blood glucose and glycated hemoglobin levels. Associations between SHR and mortality were investigated by weighted multivariable Cox regression analysis.</p><p><strong>Results: </strong>Among the 3284 participants (mean age 61 years, men prevalence 44.09%) included, 1324 (487 CVD-related) deaths occurred during a median follow-up of 87 months. The restricted cubic spline curve adjusted for all covariates showed a U-shaped and J-shaped association between SHR and all-cause or CVD mortality, respectively, with discernible inflection points at 0.86 and 0.88, respectively. The hazard ratio (95% confidence interval) was 0.117 (0.034-0.404) for SHR < 0.86 and 2.065 (1.328-3.209) for SHR ≥ 0.86 for all-cause mortality, and 0.063 (0.008-0.531) for SHR < 0.88 and 1.551 (0.770-3.124) for SHR ≥ 0.88 for CVD mortality.</p><p><strong>Conclusion: </strong>We identified U-shaped and J-shaped association between SHR and all-cause or CVD mortality, respectively, in patients with CKD. This result highlights that SHR may be potentially informative for the risk stratification of CKD patients. Given the potential limitations of residual confounding, prospective studies are needed to confirm our findings.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"69"},"PeriodicalIF":3.4000,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11854335/pdf/","citationCount":"0","resultStr":"{\"title\":\"Stress hyperglycemia ratio: a novel prognostic marker in chronic kidney disease.\",\"authors\":\"Tianquan Chen, Yijiao Zhu, Yushuang Liu, Hongxia Li, Zhe Han, Min Liu, Xia Xu, Rong Wang\",\"doi\":\"10.1186/s13098-025-01639-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The stress hyperglycemia ratio (SHR) has recently been suggested to characterize acute glycemic rise better than the admission blood glucose and to be associated with unfavorable outcomes in patients with various cardiovascular diseases. This study aimed to explore the associations between SHR and all-cause or cardiovascular disease (CVD) mortality in patients with chronic kidney disease (CKD).</p><p><strong>Methods: </strong>Adults with CKD participating in the 1999-2018 US National Health and Nutrition Examination Survey with complete SHR and follow-up data were included. SHR was calculated from fasting blood glucose and glycated hemoglobin levels. Associations between SHR and mortality were investigated by weighted multivariable Cox regression analysis.</p><p><strong>Results: </strong>Among the 3284 participants (mean age 61 years, men prevalence 44.09%) included, 1324 (487 CVD-related) deaths occurred during a median follow-up of 87 months. The restricted cubic spline curve adjusted for all covariates showed a U-shaped and J-shaped association between SHR and all-cause or CVD mortality, respectively, with discernible inflection points at 0.86 and 0.88, respectively. The hazard ratio (95% confidence interval) was 0.117 (0.034-0.404) for SHR < 0.86 and 2.065 (1.328-3.209) for SHR ≥ 0.86 for all-cause mortality, and 0.063 (0.008-0.531) for SHR < 0.88 and 1.551 (0.770-3.124) for SHR ≥ 0.88 for CVD mortality.</p><p><strong>Conclusion: </strong>We identified U-shaped and J-shaped association between SHR and all-cause or CVD mortality, respectively, in patients with CKD. This result highlights that SHR may be potentially informative for the risk stratification of CKD patients. Given the potential limitations of residual confounding, prospective studies are needed to confirm our findings.</p>\",\"PeriodicalId\":11106,\"journal\":{\"name\":\"Diabetology & Metabolic Syndrome\",\"volume\":\"17 1\",\"pages\":\"69\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-02-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11854335/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetology & Metabolic Syndrome\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13098-025-01639-2\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetology & Metabolic Syndrome","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13098-025-01639-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

背景:应激性高血糖比(SHR)最近被认为比入院血糖更好地表征急性血糖升高,并与各种心血管疾病患者的不良结局相关。本研究旨在探讨SHR与慢性肾脏疾病(CKD)患者全因或心血管疾病(CVD)死亡率之间的关系。方法:纳入参加1999-2018年美国国家健康与营养调查的成人CKD患者,并提供完整的SHR和随访数据。SHR是根据空腹血糖和糖化血红蛋白水平计算的。采用加权多变量Cox回归分析研究SHR与死亡率之间的关系。结果:在3284名参与者(平均年龄61岁,男性患病率44.09%)中,在中位随访87个月期间发生了1324例(487例心血管疾病相关)死亡。调整所有协变量后的限制性三次样条曲线显示,SHR与全因死亡率或CVD死亡率分别呈u形和j形相关,可识别的拐点分别为0.86和0.88。结论:在CKD患者中,SHR与全因或CVD死亡率分别呈u型和j型相关性。这一结果表明SHR可能为CKD患者的风险分层提供潜在的信息。考虑到残留混淆的潜在局限性,需要前瞻性研究来证实我们的发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Stress hyperglycemia ratio: a novel prognostic marker in chronic kidney disease.

Background: The stress hyperglycemia ratio (SHR) has recently been suggested to characterize acute glycemic rise better than the admission blood glucose and to be associated with unfavorable outcomes in patients with various cardiovascular diseases. This study aimed to explore the associations between SHR and all-cause or cardiovascular disease (CVD) mortality in patients with chronic kidney disease (CKD).

Methods: Adults with CKD participating in the 1999-2018 US National Health and Nutrition Examination Survey with complete SHR and follow-up data were included. SHR was calculated from fasting blood glucose and glycated hemoglobin levels. Associations between SHR and mortality were investigated by weighted multivariable Cox regression analysis.

Results: Among the 3284 participants (mean age 61 years, men prevalence 44.09%) included, 1324 (487 CVD-related) deaths occurred during a median follow-up of 87 months. The restricted cubic spline curve adjusted for all covariates showed a U-shaped and J-shaped association between SHR and all-cause or CVD mortality, respectively, with discernible inflection points at 0.86 and 0.88, respectively. The hazard ratio (95% confidence interval) was 0.117 (0.034-0.404) for SHR < 0.86 and 2.065 (1.328-3.209) for SHR ≥ 0.86 for all-cause mortality, and 0.063 (0.008-0.531) for SHR < 0.88 and 1.551 (0.770-3.124) for SHR ≥ 0.88 for CVD mortality.

Conclusion: We identified U-shaped and J-shaped association between SHR and all-cause or CVD mortality, respectively, in patients with CKD. This result highlights that SHR may be potentially informative for the risk stratification of CKD patients. Given the potential limitations of residual confounding, prospective studies are needed to confirm our findings.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Diabetology & Metabolic Syndrome
Diabetology & Metabolic Syndrome ENDOCRINOLOGY & METABOLISM-
CiteScore
6.20
自引率
0.00%
发文量
170
审稿时长
7.5 months
期刊介绍: Diabetology & Metabolic Syndrome publishes articles on all aspects of the pathophysiology of diabetes and metabolic syndrome. By publishing original material exploring any area of laboratory, animal or clinical research into diabetes and metabolic syndrome, the journal offers a high-visibility forum for new insights and discussions into the issues of importance to the relevant community.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信